Evofosfamide

A potent and selective hypoxia-activated phosphoramidate DNA cross-linking mustard; selectively potent under hypoxia and stable to liver microsomes; inhibits H246 cells and HT29 cells with IC50 of 0.1 uM and 0.2 uM respectively; active in an in vivo MIA PaCa-2 pancreatic cancer orthotopic xenograft model.Pancreatic Cancer, Phase 3 Clinical (In Vitro) :Evofosfamide (TH-302) induces γH2AX and apoptosis. Evofosfamide displays hypoxia-selective and concentration-dependent cytotoxic activity that is comparable in both p53-proficient and -deficient cells. Treatment with Evofosfamide (TH-302) alone causes an accumulation of G2/M cells. Inhibition of Chk1 by PF47736 in cells treated with Evofosfamide reduces Evofosfamide (TH-302) -mediated G2/M arrest under both normoxia and hypoxia. (In Vivo) :Evofosfamide (TH-302) is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. The mean values of normalized Ktrans decrease 69.2% for Evofosfamide (TH-302) -treated mice in Hs766t tumors, decrease 46.1% for Mia PaCa-2 tumors and increase 4.9% in SU.86.86 tumors. Both changes for Hs766t and Mia PaCa-2 treatment groups are statistically significant (P<0.01) when compare to their own control group. A significant reduction in the hypoxic fraction (HF) to 2.1%±4.7% is seen after 95% oxygen breathing (P<0.001), whereas 7% oxygen breathing significantly increase the HF to 29.5%±14.7% (P=0.029) . Exposing rhabdomyosarcoma-bearing rats to increasing oxygen conditions abolish the effect of TH-302 and reduce the T4xSV from 20.4±3.5 to 15.3±2.5 days (P=0.007), whereas control animals have an increased T4xSV. Upon combination with radiotherapy, the T4xSV of TH-302-treated tumors decrease from 30.8±5.9 (Evofosfamide (TH-302) +radiotherapy) to 25.7±2.9 days (Evofosfamide (TH-302) +radiotherapy+95% O2) .